Pipeline

Osteoarthritis

Osteoarthritis (OA) is a disease characterized by cartilage loss in joints. Its phenotypes are typically accumulated from the 50’s, and more than 50% of the population over 70’s are suffered from OA. OA phenotypes are most common for knee joints, and it is also associated with various common metabolic diseases such as obesity and diabetics.

Currently available drugs, including NSAIDs (non-steroid anti-inflammatory drugs) and pain-relievers, are limited to temporarily attenuate symptoms leaving disease conditions of joints unchanged.

ICM-203-O is a promising DMOAD (Disease-Modifying Osteoarthritis Drug) candidate, which is anticipated to render cartilage regeneration as well as to suppress chronic inflammation in the synovial joints for comprehensive improvement of joint functions.

pip_mo_001

Osteoarthritis (OA) is a disease characterized by cartilage loss in joints. Its phenotypes are typically accumulated from the 50’s, and more than 50% of the population over 70’s are suffered from OA. OA phenotypes are most common for knee joints, and it is also associated with various common metabolic diseases such as obesity and diabetics.

Currently available drugs, including NSAIDs (non-steroid anti-inflammatory drugs) and pain-relievers, are limited to temporarily attenuate symptoms leaving disease conditions of joints unchanged.

ICM-203-O is a promising DMOAD (Disease-Modifying Osteoarthritis Drug) candidate, which is anticipated to render cartilage regeneration as well as to suppress chronic inflammation in the synovial joints for comprehensive improvement of joint functions.

Slide Research Preclinical Phase 2 Phase 1 Phase 3
Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an auto-immune disease causing persistent joint destruction by chronic inflammation. No preventive treatment exists, and most therapies are only effective in delaying the onset of disease and attenuating the progression of severe symptoms.

Current drugs in use include NSAID, steroid, DMARD (Disease Modifying Anti-Rheumatoid Drug) in small compounds (DMARDc) as well as DMARD in biologics (DMARDb). If desired, two or three of these drugs can be used in combination for the treatment. In addition, if necessary, surgery may also be performed in a restricted area. However, none of these DMARDs have shown to be effective in recuperating cartilage damage.

Considering the MOA (Mode of Action) of ICM-203-R, it could be a new class of DMARD. Injection of ICM-203-R, directly into the problematic joints of the patients showing resistance or irresponsiveness to the current DMARD, is presumed not only to diminish chronic inflammation but also to restore cartilage loss. Thus, ICM-203-R may serve as an exciting next-generation DMARD distinct from the current DMARDs.

pip_mo_001

Rheumatoid arthritis (RA) is an auto-immune disease causing persistent joint destruction by chronic inflammation. No preventive treatment exists, and most therapies are only effective in delaying the onset of disease and attenuating the progression of severe symptoms.

Current drugs in use include NSAID, steroid, DMARD (Disease Modifying Anti-Rheumatoid Drug) in small compounds (DMARDc) as well as DMARD in biologics (DMARDb). If desired, two or three of these drugs can be used in combination for the treatment. In addition, if necessary, surgery may also be performed in a restricted area. However, none of these DMARDs have shown to be effective in recuperating cartilage damage.

Considering the MOA (Mode of Action) of ICM-203-R, it could be a new class of DMARD. Injection of ICM-203-R, directly into the problematic joints of the patients showing resistance or irresponsiveness to the current DMARD, is presumed not only to diminish chronic inflammation but also to restore cartilage loss. Thus, ICM-203-R may serve as an exciting next-generation DMARD distinct from the current DMARDs.

Slide Research Preclinical Phase 2 Phase 1 Phase 3
Age-related Macular Degeneration

More than 50% of blinded patients over 70’s are affected by AMD (Age-related Macular Degeneration). The degeneration of the macula, a nerve tissue located in the center of the inner retina, is accompanied by decreased vision or distorted view, and eventually reaches the conditions of blindness as the AMD pathogenesis further develops.
AMD symptoms can be divided into dry AMD and wet AMD. While the wet AMD can be treated by antibody injection inhibiting vascular invasion or by laser therapy suppressing further retinal damages, the dry AMD can only be slowed down by antioxidant treatments. Therefore, at the present time, neither wet nor dry AMD can be fundamentally cured with current approaches. Although aging, smoking, hypertension, and hyperlipidemia have been reported to increase prevalence and risk, the exact processes causing AMD pathogenesis have not been fully elucidated.

ICM is also developing AMD drug candidate, which may rescue damaged retina by supporting RPE cell viability against oxidative stresses, inhibiting chronic inflammation, as well as suppressing vascular invasion. Thus, considering these molecular actions expected from AMD drug candidate, the successful development of that as a “”first-in-Class”” AMD drug may enable a meaningful treatment for AMD by restoring a broad range of retinal functions.

e.g. Normal

e.g. AMD

pip_mo_002

Slide Research Preclinical Phase 2 Phase 1 Phase 3